Fractyl Health Overview
Valuation check: GUTS's ROE is -5.05%, below the sector sector average of -4.03%.
Get informed when a big investor buys or sells
+ Follow-505.22%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for GUTS is -5.05%. That is below the sector sector average of -4.03%. Investors often review this figure alongside Fractyl Health's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, GUTS currently prints -5.05% for ROE, while the sector average sits near -4.03%. That is roughly 12452.0% below the sector mean. Large gaps often invite a closer look at Fractyl Health's growth, margins, and balance sheet.
Return on Equity shows how effectively Fractyl Health converts resources into returns. At -5.05%, GUTS may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting GUTS's ROE (-5.05%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
